In This Article:
Exelixis (NASDAQ:EXEL) Full Year 2024 Results
Key Financial Results
-
Revenue: US$2.17b (up 19% from FY 2023).
-
Net income: US$521.3m (up 151% from FY 2023).
-
Profit margin: 24% (up from 11% in FY 2023). The increase in margin was driven by higher revenue.
-
EPS: US$1.80 (up from US$0.65 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Exelixis EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 1.7%.
The primary driver behind last 12 months revenue was the United States (U.S.) segment contributing a total revenue of US$1.82b (84% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to US$910.4m (58% of total expenses). Explore how EXEL's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are up 4.5% from a week ago.
Risk Analysis
It is worth noting though that we have found 1 warning sign for Exelixis that you need to take into consideration.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.